Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA | Xenon Pharmaceuticals Inc. (xenon-pharma.com)
XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Drug Application expected to be submitted after completion of first Phase 3 clinical trial (X-TOLE2) along with the completed Phase 2b (X-TOLE) clinical trial
Plans to initiate XEN1101 Phase 3 clinical trial (X-ACKT) in an additional epilepsy indication of primary generalized tonic clonic seizures